請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8889
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 曾宇鳳(Yufeng J Tseng) | |
dc.contributor.author | Dong-Ming Tsai | en |
dc.contributor.author | 蔡東銘 | zh_TW |
dc.date.accessioned | 2021-05-20T20:03:26Z | - |
dc.date.available | 2009-08-20 | |
dc.date.available | 2021-05-20T20:03:26Z | - |
dc.date.copyright | 2009-08-20 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-18 | |
dc.identifier.citation | 1. Zhang X, Wu H, Liao P, Li X, Ni J, Pei F: NMR-based metabonomic study on the subacute toxicity of aristolochic acid in rats. Food Chem Toxicol 2006, 44:1006-1014.
2. Sieber M, Hoffmann D, Adler M, Vaidya VS, Clement M, Bonventre JV, Zidek N, Rached E, Amberg A, Callanan JJ, et al: Comparative Analysis of Novel Noninvasive Renal Biomarkers and Metabonomic Changes in a Rat Model of Gentamicin Nephrotoxicity. Toxicol Sci 2009, 109:336-349. 3. Li X, Wang H: Aristolochic acid nephropathy: what we know and what we have to do. Nephrology (Carlton) 2004, 9:109-111. 4. Debelle FD, Vanherweghem J-L, Nortier JL: Aristolochic acid nephropathy: A worldwide problem. Kidney Int 2008, 74:158-169. 5. Feigin VL: Herbal medicine in stroke: does it have a future? Stroke 2007, 38:1734-1736. 6. Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, Kaptchuk TJ, Eisenberg DM: Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001, 135:262-268. 7. Molassiotis A, Potrata B, Cheng KK: A systematic review of the effectiveness of Chinese herbal medication in symptom management and improvement of quality of life in adult cancer patients. Complement Ther Med 2009, 17:92-120. 8. Messina BA: Herbal supplements: Facts and myths--talking to your patients about herbal supplements. J Perianesth Nurs 2006, 21:268-278. 9. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, et al.: Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993, 341:387-391. 10. Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, Salmon IJ, Deschodt-Lanckman MM, Vanherweghem JL: Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 2002, 13:431-436. 11. Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Muniz Martinez MC, Decaestecker C, Salmon I, Abramowicz D, Vanherweghem JL, Nortier J: Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis 2008, 51:471-477. 12. Cosyns JP, Dehoux JP, Guiot Y, Goebbels RM, Robert A, Bernard AM, van Ypersele de Strihou C: Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int 2001, 59:2164-2173. 13. Arlt VM, Stiborova M, Schmeiser HH: Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002, 17:265-277. 14. 刘炜: 补肺阿胶汤在呼吸系统疾患中的临床运用. 黑龙江中医药 2003:29-30. 15. 蘇喜改, 張蘭桐, 袁志芳, 田葆萍: 關木通和龍膽瀉肝丸中馬兜鈴酸A在大鼠體內的藥動學比較. 醫藥導報 2005:116-118. 16. 嚴尚學, 朱成舉, 黃德武, 陳鳳芹: 龍膽瀉肝顆粒的保肝利膽作用研究. 安徽醫科大學學報 2005:327-329. 17. Yang CS, Lin CH, Chang SH, Hsu HC: Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis 2000, 35:313-318. 18. Chang CH, Wang YM, Yang AH, Chiang SS: Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. Am J Nephrol 2001, 21:441-448. 19. Balachandran P, Wei F, Lin RC, Khan IA, Pasco DS: Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells. Kidney Int 2005, 67:1797-1805. 20. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP: Selective toxicity of aristolochic acids I and II. Drug Metab Dispos 2007, 35:1217-1222. 21. Mei N, Arlt VM, Phillips DH, Heflich RH, Chen T: DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat Res 2006, 602:83-91. 22. Mengs U: Acute toxicity of aristolochic acid in rodents. Arch Toxicol 1987, 59:328-331. 23. Mengs U, Stotzem CD: Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch Toxicol 1993, 67:307-311. 24. Sato N, Takahashi D, Chen SM, Tsuchiya R, Mukoyama T, Yamagata S, Ogawa M, Yoshida M, Kondo S, Satoh N, Ueda S: Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol 2004, 56:221-229. 25. Mengs U, Lang W, Poch JA: The carcinogenic action of aristolochic acid in rats. Archives of Toxicology 1982, 51:107-119. 26. Pozdzik AA, Salmon IJ, Debelle FD, Decaestecker C, Van den Branden C, Verbeelen D, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL: Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 2008, 73:595-607. 27. Wen YJ, Qu L, Li XM: Ischemic injury underlies the pathogenesis of aristolochic acid-induced acute kidney injury. Transl Res 2008, 152:38-46. 28. Star RA: Treatment of acute renal failure. Kidney Int 1998, 54:1817-1831. 29. Keyes R, Bagshaw SM: Early diagnosis of acute kidney injury in critically ill patients. Expert Review of Molecular Diagnostics 2008, 8:455-464. 30. Hauet T, Baumert H, Gibelin H, Hameury F, Goujon JM, Carretier M, Eugene M: Noninvasive monitoring of citrate, acetate, lactate, and renal medullary osmolyte excretion in urine as biomarkers of exposure to ischemic reperfusion injury. Cryobiology 2000, 41:280-291. 31. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, Bonventre JV: Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008, 73:863-869. 32. Albright RC, Jr.: Acute renal failure: a practical update. Mayo Clin Proc 2001, 76:67-74. 33. Shiu SH, Borevitz JO: The next generation of microarray research: applications in evolutionary and ecological genomics. Heredity 2008, 100:141-149. 34. Portilla D, Schnackenberg L, Beger RD: Metabolomics as an extension of proteomic analysis: study of acute kidney injury. Semin Nephrol 2007, 27:609-620. 35. Gates SC, Sweeley CC: Quantitative metabolic profiling based on gas chromatography. Clin Chem 1978, 24:1663-1673. 36. Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189. 37. Fiehn O: Metabolomics – the link between genotypes and phenotypes. Plant Molecular Biology 2002, 48:155-171. 38. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC: 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 1995, 67:793-811. 39. Mayr M: Metabolomics: Ready for the Prime Time? Circ Cardiovasc Genet 2008, 1:58-65. 40. Chen M, Su M, Zhao L, Jiang J, Liu P, Cheng J, Lai Y, Liu Y, Jia W: Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. J Proteome Res 2006, 5:995-1002. 41. Ni Y, Su M, Qiu Y, Chen M, Liu Y, Zhao A, Jia W: Metabolic profiling using combined GC-MS and LC-MS provides a systems understanding of aristolochic acid-induced nephrotoxicity in rat. FEBS Lett 2007, 581:707-711. 42. Zhao JY, Yan XZ, Peng SQ: Metabonomics study on nephrotoxicity of Aristolochia manshuriensis. Chinese Traditional and Herbal Drugs 2006, 37:726-730. 43. Chan W, Cai Z: Aristolochic acid induced changes in the metabolic profile of rat urine. J Pharm Biomed Anal 2008, 46:757-762. 44. Chan W, Lee KC, Liu N, Wong RN, Liu H, Cai Z: Liquid chromatography/mass spectrometry for metabonomics investigation of the biochemical effects induced by aristolochic acid in rats: the use of information-dependent acquisition for biomarker identification. Rapid Commun Mass Spectrom 2008, 22:873-880. 45. Zhang X, Wu HF, Li XJ, Pei FK, Ni JZ: NMR Studies on the Subacute Biochemical Effects of Aristolochic Acid on Rat Serum. Chinese Chemical Letters 2005, 16:1507-1510. 46. 赵剑宇, 颜贤忠, 彭双清: 利用代谢组学技术研究中药关木通的肾毒性作用. 世界科学技术-中医药现代化 2007, 9:54-59. 47. 趙劍宇, 顏賢忠, 彭雙清: 關木通腎毒性的代謝組學研究. 中草藥 2006, 37:725-730. 48. Yue H, Chan W, Guo L, Cai Z: Determination of aristolochic acid I in rat urine and plasma by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B 2009, 877:995-999. 49. Huljic S, Bruske EI, Pfitzenmaier N, O'Brien E, Dietrich DR: Species-specific toxicity of aristolochic acid (AA) in vitro. Toxicol In Vitro 2008, 22:1213-1221. 50. Dieterle F, Ross A, Schlotterbeck G, Senn H: Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem 2006, 78:4281-4290. 51. Van QN, Issaq HJ, Jiang Q, Li Q, Muschik GM, Waybright TJ, Lou H, Dean M, Uitto J, Veenstra TD: Comparison of 1D and 2D NMR spectroscopy for metabolic profiling. J Proteome Res 2008, 7:630-639. 52. Kim S, Wang Z, Hiremath B: A Bayesian approach for the alignment of high-resolution NMR spectra. Annals of Operations Research 2008, Mar. 53. Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC: Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem 2006, 78:2262-2267. 54. Park JC, Hong YS, Kim YJ, Yang JY, Kim EY, Kwack SJ, Ryu do H, Hwang GS, Lee BM: A metabonomic study on the biochemical effects of doxorubicin in rats using (1)H-NMR spectroscopy. J Toxicol Environ Health A 2009, 72:374-384. 55. Cloarec O, Dumas ME, Craig A, Barton RH, Trygg J, Hudson J, Blancher C, Gauguier D, Lindon JC, Holmes E, Nicholson J: Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem 2005, 77:1282-1289. 56. Holmes E, Bonner FW, Nicholson JK: Comparative studies on the nephrotoxicity of 2-bromoethanamine hydrobromide in the Fischer 344 rat and the multimammate desert mouse (Mastomys natalensis). Arch Toxicol 1995, 70:89-95. 57. Shackelford C, Long G, Wolf J, Okerberg C, Herbert R: Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol 2002, 30:93-96. 58. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S, et al: HMDB: the Human Metabolome Database. Nucleic Acids Res 2007, 35:D521-526. 59. Bollard ME, Keun HC, Beckonert O, Ebbels TM, Antti H, Nicholls AW, Shockcor JP, Cantor GH, Stevens G, Lindon JC, et al: Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. Toxicol Appl Pharmacol 2005, 204:135-151. 60. Martin FP, Dumas ME, Wang Y, Legido-Quigley C, Yap IK, Tang H, Zirah S, Murphy GM, Cloarec O, Lindon JC, et al: A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol 2007, 3:112. 61. Drickamer L: Rates of urine excretion by house mouse ( Mus domesticus ): Differences by age, sex, social status, and reproductive condition. Journal of Chemical Ecology 1995, 21:1481-1493. 62. Um SY, Chung MW, Kim KB, Kim SH, Oh JS, Oh HY, Lee HJ, Choi KH: Pattern recognition analysis for the prediction of adverse effects by nonsteroidal anti-inflammatory drugs using 1H NMR-based metabolomics in rats. Anal Chem 2009, 81:4734-4741. 63. Saric J, Li JV, Wang Y, Keiser J, Bundy JG, Holmes E, Utzinger J: Metabolic Profiling of an Echinostoma caproni Infection in the Mouse for Biomarker Discovery. PLoS Negl Trop Dis 2008, 2:e254. 64. Wang Y, Holmes E, Nicholson JK, Cloarec O, Chollet J, Tanner M, Singer BH, Utzinger J: Metabonomic investigations in mice infected with Schistosoma mansoni: An approach for biomarker identification. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:12676-12681. 65. Espandiari P, Zhang J, Rosenzweig BA, Vaidya VS, Sun J, Schnackenberg L, Herman EH, Knapton A, Bonventre JV, Beger RD, et al: The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Toxicol Sci 2007, 99:637-648. 66. Golotvin S, Williams A: Improved baseline recognition and modeling of FT NMR spectra. J Magn Reson 2000, 146:122-125. 67. Suzuki H, Sasaki R, Ogata Y, Nakamura Y, Sakurai N, Kitajima M, Takayama H, Kanaya S, Aoki K, Shibata D, Saito K: Metabolic profiling of flavonoids in Lotus japonicus using liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry. Phytochemistry 2008, 69:99-111. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8889 | - |
dc.description.abstract | 馬兜鈴酸具腎毒性,過去傳統中藥裏常使用的馬兜鈴酸屬的植物含有此物質。本實驗研究馬兜鈴酸標準品、馬兜鈴草果實及含馬兜鈴草的中藥複方補肺阿膠湯3種物質在囓齒類動物上的腎毒性,並以代謝體學方法分析尿液核磁共振氫譜在馬兜鈴酸腎病變中的變化。實驗目的在初步探討如何以容易取得之尿液來建立腎毒性之診斷模式。實驗共分4部份進行,一為大鼠以胃灌食馬兜鈴酸標準品測試。二為小鼠以胃灌食馬兜鈴酸標準品測試。三為小鼠以胃灌食馬兜鈴草果粉末測試。四為小鼠以胃灌食補肺阿膠湯粉末測試。實驗收集每日尿液樣本並冷凍保存以備分析,實驗結束後犧牲鼠隻取其肝腎做病理分析。
結果:大鼠馬兜鈴酸標準品給藥5劑後腎病理檢查顯示高劑量組有1-3度的急性腎小管間質病變。小鼠馬兜鈴酸標準品給藥10劑後,高低劑量組皆有3-4度的急性腎小管間質病變。小鼠馬兜鈴草給藥21劑後,低及中劑量組有1-2度而高劑量組有3-4度之急性腎小管間質病變。小鼠補肺阿膠湯給藥20劑後,低劑量組有2度而高劑量組有3-4度之急性腎小管間質病變。尿液核磁共振氫譜以主成份分析法分析各實驗中各個組別在同一天之分數圖,結果發現大鼠馬兜鈴酸標準品給藥後2天3組皆能分群。小鼠馬兜鈴酸標準品給藥後8天高劑量組能與其他2組分群,10天時給藥的2組能與對照組分群。小鼠馬兜鈴草給藥後8天高劑量組能與其他3組分群,10天時高劑量與中劑量組能與對照及低劑量組分群。小鼠補肺阿膠湯各組則至給藥後16天仍未見分群。以t檢定比對給藥組與對照組尿液中內生代謝物隨時間相對濃度變化發現大鼠馬兜鈴酸標準品實驗早期時甘氨酸、琥珀酸、氧化三甲胺及2-酮戊二酸有下降的現象,而到晚期時糖類、尿囊素、肌酐、二甲基甘胺酸、2-酮戊二酸及氧化三甲胺有上升現象(p < 0.05)。小鼠馬兜鈴酸酸標準品實驗之代謝物濃度有明顯變化者相對較少,但在實驗後期可見給藥組有丙氨酸、乳酸及甲酸平均濃度相對增加之現象。 結論:馬兜鈴酸標準品及含有此物質的中草藥馬兜鈴和其複方補肺阿膠湯在鼠類是有腎毒性的。以主成份分析尿液的核磁共振氫譜可以分辨出有發生腎病變的組別,其代謝體的濃度變化也可進一步分析找出相關的生物標誌。但在含低劑量馬兜鈴酸的複方補肺阿膠湯在本實驗中則未能以主成份分析法從尿液分析出小鼠發生的腎病變,這有待進一步的代謝體學分析研究。 | zh_TW |
dc.description.abstract | Aristolochic acid (AA) is a potent nephrotoxic agent that can be found in several herbs of the genus Aristolochia. It was once commonly used in traditional Chinese medicine remedy. In this study, we applied our metabolomics platform of the 1H NMR spectroscopy on urine with principal component analysis (PCA) to detect and further dissect the nephrotoxicity in rodent of four AA containing materials, AA standard, Madouling, an AA containing herb Aristolochia contorta and Bu-Fei-A-Jiau-Tang (BFAJT), a herb compound containing Aristolochia contorta. The aim was to use the easy available urine samples to establish a model for early diagnosis of nephrotoxicity. The experiment was divided into four parts. The first was rat AA experiment. The second was mouse AA experiment. The third was mouse Madouling experiment. The fourth was mouse BFAJT experiment. Urine samples were collected daily and freeze-dried for storage. All animals were euthanized after experiment and their kidneys and livers procured for pathological studies.
Results: In the rat AA experiment, pathology showed grade (gr.) 1-3 acute renal tubulointerstitial necrotic change (ATIN) after 5 doses in the high dose group. In the mouse AA experiment, 10 doses were given. Both high and low dose group showed gr. 3-4 ATIN. In the mouse Madouling experiment, 21 doses were given. It was gr. 1-2 for low and moderate groups, and gr. 3-4 ATIN for the high dose group. In the BFAJT experiment, 20 doses were given. It was gr. 2 ATIN in the low dose group and gr. 3-4 in the high dose group. PCA scoring plots for the urine NMR spectral chemical shifts variables showed early cluster at 2 day and later for each group in the rat AA experiment. In the mouse AA experiment, the high dose group was clustered from the other 2 groups at day 8. It was at day 10 that the 2 dose groups were clustered from the control group. In the mouse Madouling experiment, the high dose group clustered from all other 3 groups. It was at day 10 that the high dose and the moderate dose groups clustered together from the other 2 groups. In the BFAJT experiment, PCA scoring plots failed to classify across control and dose groups even at day 16. The endogenous metabolites assigned from NMR spectroscopy and their integral concentration among dose and control groups were tested by t-test. In the rat AA experiment glycine, succinate, 2-oxoglutarate and trimethylamine-N-oxide (TMAO) were decreased in the dose groups in earlier days of the experiment. At later days, sugar, allantoin, creatine, dimethylglycine, 2-oxoglutarate and TMAO were increased in the dose groups (p < 0.05). In the mouse AA experiment no significant metabolite difference was noted, only alanine, lactate and formate had more than two fold change at day 10. In conclusion, AA standard, Madouling and BFAJT were all nephrotoxic. PCA scoring plots for the urine NMR spectroscopy collected from living animals showed the ability to classify the dose and control groups days before confirming the renal pathology. But toxicity classifying failed in the mouse BFAJT experiment by PCA scoring plot. Further metabolomics study is expected to resolve this issue. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:03:26Z (GMT). No. of bitstreams: 1 ntu-98-R96945041-1.pdf: 2481287 bytes, checksum: aa39c1b15f04ff83e961686efea94c6b (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 致謝 ii
摘要 iii Abstract v Contents viii List of Figures xi List of Tables xxii Chapter 1. Background and Literature Review 1 1.1 Introduction 1 1.2 Literature Review 1 1.2.1 Aristolochic acid nephropathy 1 1.2.1.1 Aristolochia herbs 1 1.2.1.2 Toxicology Related to Aristolochic Acids 3 1.2.1.3 Evaluation of Aristolochic Acid Nephropathy 5 1.2.2 Metabolomics 7 1.2.2.1 Definition and Technologies used 7 1.2.2.1.1 NMR Spectroscopy 9 1.2.2.2 Metabolomics in Toxicological Studies 11 1.2.3 Chemometrics and Pattern Recognition Technology 13 1.2.3.1 Data Processing of NMR Spectroscopy 13 1.2.3.2 Unsupervised Pattern Recognition 15 1.2.3.2.1 Principal Component Analysis 15 1.2.3.3 Metabolites Assignment for NMR Spectroscopy 16 1.3 Aim 17 Chapter 2. Materials and Methods 19 2.1 Aristolochic Acid Sources 19 2.2 In vivo Experiments and Sample Preparation 19 2.2.1 Rat 20 2.2.2 Mouse 21 2.3 NMR Measurement and Pattern Recognition Investigation 23 2.3.1 NMR Spectra Acquisition 23 2.3.2 Spectral Data Processing 23 2.3.3 Statistical Methods 24 2.3.3.1 PCA 24 2.4 Metabolite Assignment 25 Chapter 3. Results 26 3.1 In vivo Experiment 26 3.1.1 Rat on AA 26 3.1.1.1 Clinical Signs and Biochemical Parameters 26 3.1.1.2 Pathology 26 3.1.1.3 Metabolomic Profiling 26 3.1.2 Mouse on AA 27 3.1.2.1 Clinical Signs and Biochemical Parameters 28 3.1.2.2 Pathology 28 3.1.2.3 Metabolomic Profiling 28 3.1.3 Mouse on Madouling 29 3.1.3.1 Clinical Signs and Biochemical Parameters 30 3.1.3.2 Pathology 30 3.1.3.3 Metabolomic Profiling 30 3.1.4 Mouse on Bu-Fei-A-Jiau-Tang 31 3.1.4.1 Clinical Signs and Biochemical Parameters 31 3.1.4.2 Pathology 32 3.1.4.3 Metabolomic Profiling 32 Chapter 4. Discussion 34 Chapter 5. Conclusion and Future Work 43 Appendix 83 Bibliography 88 List of Figures Figure 1. Chemical structure of aristolochic acid I (AA-I) and II (AA-II). 44 Figure 2. Cascade of '-omics'. Metabolomics studies the end point of biological complex system. 44 Figure 3. Illustrations of principles of nuclear magnetic resonance. The moment μ comes from the momentum of a proton spin (a). When there is an external magnetic field B0, a Larmor precession (ωL) occurs (b). Energy status of protons are divided into two energy level under external magnetic field (c). A radio frequency pulse (RF+) along the y axis will rotate the internal magnetic field produced by Larmor precession M0, which is directed along the z axis to x axis (d). After the radio frequency pulse ceased (RF-), the rotated magnetic field will relax to two magnetic vectors MZ and MXY (e). 45 Figure 4. Mean body weight (BW) of three groups of rat in AA experiment. The mean BW of dosed groups was tested with the same group at day 1 (D1). Mean BW of high AA dosed group was significantly different from that at D1 at all other days. It was day 0 (D0) and day 5 for low dose group. * p < 0.05, paired t-test. Error bars are the standard deviation of group means. Groups were C: control (n=3), L: low (n=3), H: high (n=3). 47 Figure 5. Mean urine volume (U-vol) for three groups of rat during AA dosing. Daily group mean urine volume was compared with the mean urine volume of control group at the same day. The mean U-vol of the two dosed groups was not significantly different from the control group (p > 0.05, paired t-test). Error bars are the standard deviation of group means. 48 Figure 6. Mean serum urea nitrogen (UN) for three groups of rat in AA experiment. UN of high dose groups on day 0, 2, 4 (D0, D2 and D4) was significant different from their respective group mean at day 1 (D1). Error bars are the standard deviation of group means. (* p < 0.05, paired t test). 49 Figure 7. Renal histopathological findings in the rat AA experiment. Normal architecture of kidney in No. 1 rat of control group (A and B. 400x). A pattern of acute proximal renal tubular necrosis (arrow) was note in high dose AA group rats (C. 100x, D. 200x, E. 400x). No morphological change was noted in the glomerulus (arrow) (F. 400x). H&E stain. 50 Figure 8. PCA scoring plots of rat urine NMR spectra showed daily change before and after AA standard exposure. All 3 groups clustered together on day 0 under fasting status. Control, low dose (4 mg/day) and high dose (8 mg/day) groups were clustered separately from day 2 (D2) to day 5 (D5). The labels in day 5 was the individual urine sample, 1-3: control, 4-6: low dose and 7-9: high dose group. The x-axis of all plots was the value of PC1 and y-axis PC2. The sum of PC1 and PC2 is 26.2%. 51 Figure 9. Loading plot of rat urine NMR spectra. Several variables were significantly deviated from the center with Euclidean distance (p<0.05). Their binned ppm values were 1.38, 3.06, 3.18, 3.22, 3.34, 3.38, 3.50, 3.54, 3.62, 3.66, 3.70, 3.74, 3.78, 3.98, 4.50 and 7.58. 52 Figure 10. Representative urine NMR spectra of a rat in the high dose AA group. 53 Figure 11. Relative concentration ratio of assigned metabolites to creatinine in rat AA experiment. Each standard deviation bar is the mean of metabolite concentration of the same dosed group (C: control, L: low and H: high) on the same day from day 1 (D1) to day 5 (D5). Student paired t-test was used for estimating significant difference between control and either low or high dosed group at the same day. Parenthesis below the name of metabolites denotes the chemical shifts range for integration. Here shows several metabolites within 1.32 to 3.03 ppm. * p < 0.05. 54 Figure 11 (continued). Metabolite concentration changes for assigned endogenous metabolites with 3.26 and 8.45 ppm. 55 Figure 12. Mean body weight (BW) changes in three groups of mouse in AA experiment. The group mean BW of each day was tested with that at day 0 (D0) of the same group. * p < 0.05, t-test. C: control (n=3), L: low (n=3), H: high (n=4 D0-D8, n=3 at D10 and D11 ) dose group. 56 Figure 13. Mean serum urea nitrogen (UN) for three groups of mouse in AA experiment. Mean UN of each group at Day 4, 8 and 11 was compared with day 2 of the same group. * p < 0.05, t-test. Mouse groups were C: control (n=3), L: low (n=3), H: high (n=4 D2, 4 and 8, n=3 at D11 ). 57 Figure 14. Mean serum creatinine (Cr) for three groups of mouse in AA experiment. Cr of the high dose group increased more from day 4 (D4) to day 11 (D11) than other groups. Mouse groups were C: control (n=3), L: low (n=3), H: high (n=4 D2, 4 and 8, n=3 at D11 ). 58 Figure 15. Histopathological findings of mouse kidneys dosed with AA standard. No significant change of renal tubules and glomeruli of kidney in a mouse of control group (A. 200x, B. 400x). A mouse of low dose AA (5 mg/kg/day) group showed focal moderate (3) to severe acute proximal tubular necrosis and dilation with hyaline casts (C. 200x, D. 400x). A mouse of high dose AA (7.5 mg/kg/day) group showed focal moderately severe (4) acute proximal tubular necrosis with hyaline casts (E. 200x, F. 400x). No morphological change was noted in the glomeruli. H&E stain. 59 Figure 16. Representative urine NMR spectra of a mouse from the high dose AA group. 60 Figure 17. PCA scoring plots of mouse urine NMR spectra showed clustering before and after AA standard exposure in the mouse AA experiment. The chemical shifts range selected was from 1 to 4.5 ppm. The control group and the dose groups were clustered separately at day 3 and later except a mouse of the low dose group labeled 'L2' at day 8. There was no urine sample at D10 for a mouse of high dosed group labeled 'H1'. The x-axis of all plots was the value of PC1 and y-axis PC2. The sum of PC1 and PC2 is 43.7%. 61 Figure 18. Loading plot of mouse urine NMR spectra of the AA experiment. Several variables were significantly deviated from the center with Euclidean distance (p < 0.1, green; p < 0.05, red). Their binned ppm values were 0.66, 0.98, 1.02, 1.06, 1.74, 2.66, 3.46, 3.50, 3.54, 3.58, 3.74, 3.78, 3.86, 3.94, 4.30, 7.42, 7.66, 8.34, 8.38 and 8.98. 62 Figure 19. Major endogenous metabolites profile in the mouse AA experiment. Relative concentration ratio of assigned metabolites to creatinine. Each standard deviation bar is the mean of metabolite concentration of the same dosed group (C: control, L: low (5 mg/kg/day) and H: high (7.5 mg/kg/day)) on the same day from day 1 (D1) to day 10 (D10). Parenthesis below the name of metabolites denotes the chemical shifts range for integration. * p < 0.05. 63 Figure 19 (continued). Metabolite concentration changes among three groups of mouse dosed with AA. 64 Figure 20. Mean body weight (BW) changes in groups of mouse dosed with Madouling. C: control, L: low (559 mg/kg/day), M: moderate (1118 mg/kg/day), H: high (2236 mg/kg/day). Each mean BW of the same group at different day was compared with its mean BW at day 0 (D0). 65 Figure 21. Mean serum urea nitrogen (UN) for groups of mouse in Madouling experiment. Each mean BW of the same group at different day was compared with its mean UN at day 0 (D0). UN was not increased in all group until day 20 (D20) in the high dose group. There were 3 mice for each group and UN of one mouse in the high dose group was not detected at 9 and day 20 due to mortality. * p < 0.05, t-test. 66 Figure 22. Mean serum creatinine (Cr) for four groups of mouse in Madouling experiment. No difference of mean Cr change for each day creatinine as compared to day 0 of the same group. Mouse groups were C: control (n=3), M: moderate (n=3),L: low (n=3), H: high (n=3 D2, 4 and 6, n=2 at D9 and D20). 67 Figure 23. Histopathological findings of mouse kidneys dosed with Madouling at day 20. A mouse of low dose (559 mg/kg/day) group showed focal slight acute proximal tubular degeneration with cellular swelling (A. 200x, B. 400x). The moderate dose (1118 mg/kg/day) group showed focal moderate acute proximal tubular necrosis with dilation (C. 200x, D. 400x). The high dose (2236 mg/kg/day) group showed focal moderate/serve acute proximal tubular necrosis with dilation (E. 200x, F. 400x). No morphological change was noted in the glomerulus. H&E stain. 68 Figure 24. Representative urine NMR spectra of a mouse of high dose (2236 mg/kg/day) group in the Madouling experiment. 69 Figure 25. PCA scoring plots of mouse urine NMR spectra showed daily change before (D0) and after Madouling (AC) exposure. At day 8 (D8), the high dose group showed separation from other groups. At day 10 (D10) the cluster of two dose groups were separated from the control group. Scoring points labeled M1-3 were individual mouse of the moderate dose group. The sum of PC1 and PC2 is 22.6%. 70 Figure 26. Loading plot of mouse urine NMR spectra in the Madouling experiment. Several variables were significantly deviated from the center with Euclidean distance (p < 0.05, red). Their binned ppm values were 0.94, 1.02, 1.06, 1.34, 1.70, 1.74, 1.90, 2.14, 2.62, 2.78, 3.50, 3.74, 3.78, 4.10, 4.14, 6.90, 6.94, 7.14 and 8.02. 71 Figure 27. Relative concentration ratio of assigned metabolites to creatinine in the mouse Madouling experiment. Each standard deviation bar is the mean of metabolite concentration of the same dosed group (C: control, L: low (559 mg/kg/day), M: moderate (1118 mg/kg/day) and H: high (2236 mg/kg/day)) at day 0, 1, 3 and 8. Parenthesis below the name of metabolites denotes the chemical shifts range for integration. * p < 0.05. 72 Figure 27 (continued). Metabolite concentration changes among four groups of mouse dosed with Madouling. 73 Figure 28. Mean body weight (BW) changes in groups of mouse dosed with Bu-Fei-A-Jiau-Tang (BFAJT). C: control (n=3), L: low (n=3), H: high (n=3). Each group mean BW at different day was compared with day 0 (D0) of the same group. The mean BW was significantly different at day 10 (D10) and day 20 (D20) for high dose (4 g/kg/day) group and at D20 for low dose (2 g/kg/day) group. * p < 0.05, paired t-test. 74 Figure 29. Mean serum urea nitrogen (UN) for groups of mouse during Bu-Fei-A-Jiau-Tang dosing. The mean UN of high dose group at day 20 (D20) was significantly higher than its mean UN at day 0 (D0). The standard deviation of group means are shown in stick arrows. * p < 0.05 as comparing with control group at the same day. 75 Figure 30. Histopathological findings of mouse kidneys dosed with BFAJT after dosing for 20 days. A mouse of low dose (2 g/kg/day) group showed focal slight acute proximal tubular degeneration with cellular swelling (A. 200x, B. 400x). The high dose (4 g/kg/day) group showed focal moderate acute proximal tubular necrosis with dilation (C. 200x, D. 400x). No morphological change was noted in the glomerulus. H&E stain. 76 Figure 31. Representative urine NMR spectra of a mouse of high dose (2236 mg/kg/day) group in the BFAJT experiment. 77 Figure 32. PCA scoring plots of mouse urine NMR spectra in the Bu-Fei-A-Jiau-Tang (BF) experiment. No group clustering from day 0 to day 16 (D16). The sum of PC1 and PC2 is 24%. 78 Figure 33. Metabolites in their metabolic pathways and concentration changes. Comparison of our rat AA experiment with two other experiments usign rats are shown in the left lower panels of metabolites detected in our urine NMR spectroscopy. The most left panel indicated metabolite fold change between the high dose group and the control group at the time-point of day 5. The right next panel indicated changes in an rat AA experiment reported by Zhang et al. with data collected at day 10 with 10 mg/kg/day AA in the initial 5 days [1]. The right most panel column indicated changes in an gentamicin experiment with a dose of 60 mg/kg/day for the upper panel and 120 mg/kg/day for the lower panel [2]. The chemicals of both experiments were given subcutaneously . 81 Figure 34. Metabolites in their metabolic pathways and concentration changes. Metabolites detected from urine NMR spectroscopy were compared among three mouse experiments. The upper row showed metabolites changes relative to the control group at day 5 of the mouse AA experiment. The left panel indicated low and the right high dose group. The middle row showed metabolites changes relative to the control group at day 10 of the mouse Madouling experiment. The left panel indicated low, the middle moderate and the right high dose group. The lower row showed metabolites changes relative to the control group at day 10 (left panel) and 16 (right panel) of the high dose group in the mouse BFAJT experiment. 82 Figure A.1. The raw data contained 16384 measurement and the approximated data interpolated the measurement width to 0.0001 ppm. 83 Figure A.2. A spectrum before and after baseline correction. OS: original spectrum, CL: correction baseline, CS: corrected spectrum 85 List of Tables Table 1. Summary of the four experiments for aristolochic acid nephrotoxicity 46 Table 2. Metabolomics studies on AA nephrotoxicity and their PCA results 79 Table 3. Pathological grading of reanl injury in all four experiments 80 | |
dc.language.iso | en | |
dc.title | 馬兜鈴酸腎毒性在囓齒類動物的代謝體學研究 | zh_TW |
dc.title | Metabolomics Study of Aristolochic Acid Nephrotoxicity in Rodents | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 郭錦樺(Ching-Hua Kuo) | |
dc.contributor.oralexamcommittee | 康照洲(Jaw-Jou Kang) | |
dc.subject.keyword | 馬兜鈴酸,馬兜鈴,補肺阿膠湯,主成份分析,代謝體學,核磁共振氫譜, | zh_TW |
dc.subject.keyword | Aristolochic Acid,Aristolochia contorta,Madouling,Bu-Fei-A-Jiau-Tang,1H NMR Spectroscopy,Metabolomics,Principal Component Analysis,Nephrotoxicity, | en |
dc.relation.page | 98 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2009-08-18 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf | 2.42 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。